Cargando…

Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer

PURPOSE: Hypoxia is widely known as one of the mechanisms of chemoresistance and as an environmental condition which triggers invasion and metastasis of cancer. Evofosfamide is a hypoxia-activated prodrug of the cytotoxin bromo-isophosphoramide mustard conjugated with 2-nitroimidazole. Biliary tract...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoon, Jeesun, Kang, Seo Young, Lee, Kyung-Hun, Cheon, Gi Jeong, Oh, Do-Youn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053876/ https://www.ncbi.nlm.nih.gov/pubmed/33091966 http://dx.doi.org/10.4143/crt.2020.577

Ejemplares similares

(18)F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition
por: Reeves, Kirsten M., et al.
Publicado: (2022)

Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models
por: Stokes, Ashley M., et al.
Publicado: (2016)

The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy
por: Nytko, Katarzyna J., et al.
Publicado: (2017)

Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET
por: Wiedenmann, Nicole, et al.
Publicado: (2018)

The role of necrosis, acute hypoxia and chronic hypoxia in (18)F-FMISO PET image contrast: a computational modelling study
por: Warren, Daniel R, et al.
Publicado: (2016)

Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET
por: Wiedenmann, Nicole, et al.
Publicado: (2018)

Monitoring Tumor Hypoxia Using (18)F-FMISO PET and Pharmacokinetics Modeling after Photodynamic Therapy
por: Tong, Xiao, et al.
Publicado: (2016)

Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo
por: Huang, Yan, et al.
Publicado: (2018)

Elimination of tumor hypoxia by eribulin demonstrated by (18)F-FMISO hypoxia imaging in human tumor xenograft models
por: Zhao, Songji, et al.
Publicado: (2019)

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models()
por: Kumar, Sushil, et al.
Publicado: (2018)

A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using (18)F-FMISO-PET
por: Rockne, Russell C., et al.
Publicado: (2015)

Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients
por: Bandurska-Luque, Anna, et al.
Publicado: (2019)

Biodistribution and radiation dosimetry of the novel hypoxia PET probe [(18)F]DiFA and comparison with [(18)F]FMISO
por: Watanabe, Shiro, et al.
Publicado: (2019)

Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and (18)F-FMISO PET
por: Huang, Shiliang, et al.
Publicado: (2021)

First Comparison between [18f]-FMISO and [18f]-Faza for Preoperative Pet Imaging of Hypoxia in Lung Cancer
por: Thureau, Sébastien, et al.
Publicado: (2021)

Synthesis of [(18)F]FMISO, a hypoxia-specific imaging probe for PET, an overview from a radiochemist’s perspective
por: Kniess, Torsten, et al.
Publicado: (2023)

Usefulness of FMISO—PET for Glioma Analysis
por: Kobayashi, Hiroyuki, et al.
Publicado: (2013)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in osteolytic breast cancer murine models
por: Liapis, Vasilios, et al.
Publicado: (2016)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
por: Liapis, Vasilios, et al.
Publicado: (2017)

Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma
por: Brenner, Andrew J., et al.
Publicado: (2021)

(18)F-FMISO-PET Hypoxia Monitoring for Head-and-Neck Cancer Patients: Radiomics Analyses Predict the Outcome of Chemo-Radiotherapy
por: Carles, Montserrat, et al.
Publicado: (2021)

Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models
por: Harms, Julia K., et al.
Publicado: (2019)

Increased [(18)F]FMISO accumulation under hypoxia by multidrug-resistant protein 1 inhibitors
por: Shimizu, Yoichi, et al.
Publicado: (2021)

Hypoxia Imaging Using PET and SPECT: The Effects of Anesthetic and Carrier Gas on [(64)Cu]-ATSM, [(99m)Tc]-HL91 and [(18)F]-FMISO Tumor Hypoxia Accumulation
por: Kersemans, Veerle, et al.
Publicado: (2011)

Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer
por: Seo, Hye-Rim, et al.
Publicado: (2022)

Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide
por: Lodi, Alessia, et al.
Publicado: (2022)

Kinetic Evaluation of the Hypoxia Radiotracers [(18)F]FMISO and [(18)F]FAZA in Dogs with Spontaneous Tumors Using Dynamic PET/CT Imaging
por: Choen, Sangkyung, et al.
Publicado: (2022)

An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect()()
por: Hong, Cho Rong, et al.
Publicado: (2018)

The accumulation mechanism of the hypoxia imaging probe “FMISO” by imaging mass spectrometry: possible involvement of low-molecular metabolites
por: Masaki, Yukiko, et al.
Publicado: (2015)

A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model()()
por: Hajj, Carla, et al.
Publicado: (2017)

Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas
por: Suzuki, Kenta, et al.
Publicado: (2021)

Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, (18)F-FMISO PET, and (18)F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
por: Collet, Solène, et al.
Publicado: (2021)

Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy
por: Yoo, Shin Hye, et al.
Publicado: (2021)

Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation
por: Rühle, Alexander, et al.
Publicado: (2020)

[(18)F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [(18)F]FDG PET/CT approach
por: Tanguy, Julie, et al.
Publicado: (2021)

FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer
por: Thureau, Sébastien, et al.
Publicado: (2018)

ANGI-1 ASSESSING THE THERAPEUTIC EFFECT OF BEVACIZUMAB USING FMISO-PET IN GBM THERAPY
por: Suzuki, Tomoya, et al.
Publicado: (2022)

PET Imaging of Cardiac Hypoxia: Hitting Hypoxia Where It Hurts
por: Pell, Victoria R., et al.
Publicado: (2018)

A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients
por: Larue, Ruben T. H. M., et al.
Publicado: (2016)

PET imaging of tumour hypoxia
por: Padhani, Anwar
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_0l8lfcd0ecnii7j36qg8i87fuq